Vitamins, Minerals And Supplements (VMS) CDMO Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Vitamins, Minerals And Supplements (VMS) CDMO Market Trends and Insights

Rising Consumer Health Awareness and Preventive Healthcare

Consumers are allocating discretionary income to supplements positioned for immune, cognitive, and metabolic support, decoupling preventive spending from traditional prescription budgets. The CDC recorded that 58.1% of adults in the United States used supplements in 2024, up from 52.3% in 2020.^{[1]Centers for Disease Control and Prevention, “Dietary Supplement Use Among U.S. Adults,” cdc.gov} Demand now favors CDMOs that can create condition-specific blends backed by robust analytical data rather than generic multivitamins. In response, leading facilities have installed high-performance liquid chromatography and mass spectrometry labs to validate potency and purity. The Vitamins, Minerals, and Supplements CDMO market benefits when partners also house in-house regulatory teams capable of navigating the FDA structure/function claim guidance. As public sentiment shifts from reactive treatment to proactive supplementation, CDMOs that offer bioavailability optimization secure premium pricing and more extended contracts.

Growing Outsourcing Trend Among Brands

Pharmaceutical and consumer-health companies are liquidating manufacturing assets to focus on brand equity and digital distribution, mirroring trends seen in biologics. Outsourcing lets marketers launch seasonal SKUs without bearing the fixed cost of idle capacity. CDMOs able to run small batches with rapid line changeovers can charge 15-20% price premiums and thus expand margin. However, the same dependence creates allocation risk during production peaks, a factor pushing brands toward long-term supply agreements. The relentless outsourcing wave is one of the strongest structurally positive forces for the Vitamins, Minerals, and Supplements CDMO market.

Rapid Adoption of Gummy, Liquid & Other Experiential Formats

Gummies have reframed supplement intake as an enjoyable routine, attracting younger consumers who equate pills with sickness. Robinson Pharma expanded softgel capacity to 23 billion units in 2025 to meet brand demand for oil-based gummies that mask the bitterness of botanicals. Liquid shots and effervescent tablets satisfy sports-nutrition users who value fast absorption. Each format requires different clean-room classes and process controls, raising the technical bar for entrants. CDMOs that invested early in multi-format capability, such as Catalent’s global network, can cross-sell services and lock in multiyear contracts, reinforcing the scalability of the Vitamins, Minerals, and Supplements CDMO market.

Aging Population & Chronic-Disease Specific VMS Demand

The share of people aged 65+ will nearly double from 10.3% in 2024 to 20.7% by 2074.^{[2]World Health Organization, “Ageing and Health,” who.int} Older adults favor supplements for bone, heart, and cognitive health, yet require low-sugar, low-sodium formulations. Brand owners increasingly request personalized packs derived from genetic tests, which force CDMOs to handle thousands of SKUs with small lot sizes. Those facilities that achieve cost-per-dose parity with generic OTC drugs through continuous manufacturing are best placed to win senior segments, further amplifying growth in the Vitamins, Minerals, and Supplements CDMO market.

Volatile Raw-material Prices & Ingredient Shortages

Vitamin and mineral commodity markets experienced severe disruptions in recent years, with DSM-Firmenich flagging shortages of vitamin B12 and vitamin D3 in Q3 and Q4 due to production outages at Chinese fermentation plants and regulatory crackdowns on environmental compliance. CDMOs lack the purchasing power of vertically integrated pharmaceutical companies, forcing them to hold 90-day inventory buffers that tie up working capital and compress margins. Botanical extracts face additional volatility: turmeric prices surged 0.86% in 2024 following monsoon failures in India, and ashwagandha shortages emerged as demand from sports-nutrition brands outstripped cultivation capacity. The issue is compounded by geopolitical risk; the majority of global vitamin C production originates in China, creating a single-source dependency that leaves CDMOs vulnerable to export restrictions or trade tariffs. Brands are responding by demanding dual-sourcing clauses in CDMO contracts, but smaller manufacturers lack the supplier relationships to comply with them.

High Capex for Multi-format Production Lines

Establishing a multi-format CDMO facility requires USD 50 million to USD 100 million in upfront capital, covering tablet presses, softgel encapsulation lines, gummy depositors, and liquid filling systems, each with distinct clean-room classifications and validation protocols. Robinson Pharma's May 2025 announcement of 10 new softgel machines expanding capacity to 23 billion units annually illustrates the scale of investment needed to compete for tier-1 brand contracts. Mid-tier CDMOs face a strategic dilemma: invest in gummy lines to capture high-margin experiential formats, or double down on tablet efficiency to defend commodity volume. The risk of format obsolescence complicates the decision; if consumer preferences shift from gummies to sublingual films or orally disintegrating tablets, a USD 20 million gummy line becomes a stranded asset. Financing is also challenging, as banks view CDMO equipment as specialized collateral with limited resale value. This dynamic favors large, diversified players such as Catalent and Lonza, which can amortize capex across multiple product categories and geographies. At the same time, smaller CDMOs increasingly pursue toll-manufacturing agreements that cap margin upside but eliminate balance-sheet risk.

Segment Analysis

By Dosage Form: Softgels Lead Innovation Despite Tablet Dominance

In 2025, tablets accounted for 40.09% of revenue, giving them the largest share of the Vitamins, Minerals, and Supplements CDMO market. Cost efficiency and proven high-speed packaging up to 500 bottles per minute anchor their continued relevance. Yet tablets face perception headwinds among younger users who link pills to illness. Softgels answer that challenge by improving the bioavailability of fat-soluble vitamins and omega-3 oils, and they are projected to register a 12.02% CAGR through 2031, the fastest among forms. 

Softgel production involves ISO 7 clean rooms and costly encapsulators, barriers that keep competition low and margins higher. Chewable softgels, which blend oil-based payloads with a gummy-like mouthfeel, are now targeting pediatric omega-3 segments. Acceptance of self-emulsifying systems under FDA GRAS has further widened the application scope. These dynamics collectively underpin the expanding role of softgels within the broader Vitamins, Minerals, and Supplements CDMO market.

Note: Segment shares of all individual segments available upon report purchase

By Product Type: Sports Nutrition Outpaces Traditional Supplements

Dietary supplements accounted for 39.26% of sales in 2025, underscoring their core role in the Vitamins, Minerals, and Supplements CDMO market. However, sports nutrition is forecast to grow at a 12.89% CAGR, driven by rising interest in protein isolates, collagen peptides, and BCAAs. The category’s demographics now range from competitive athletes to seniors combating muscle loss. 

Plant-based proteins, such as pea, rice, and hemp, garner share on allergen and sustainability grounds but pose flavor-masking and amino-acid-profile challenges. CDMOs with flavor-engineering capabilities gain an edge. Beauty-from-within offerings that merge hydrolyzed collagen with vitamin C and hyaluronic acid form a premium sub-niche. Functional foods and beverages round out consumer-friendly formats, turning everyday consumption occasions into supplementation points and magnifying demand across the Vitamins, Minerals, and Supplements CDMO market.

By Service Type: Formulation Services Capture Premium Margins

Manufacturing and packaging accounted for 37.90% of 2025 revenue, yet formulation and product development services will expand at a 11.09% CAGR through 2031 as brands seek novel delivery technologies. Third-party potency verification is also soaring; NSF GMP and USP Verified audits now occur quarterly, raising the technical bar. 

Liposomal encapsulation can triple or quintuple bioavailability by surrounding actives with phospholipid bilayers, while micellar solubilization enables clear liquids for fat-soluble vitamins. Both require high-pressure homogenizers and advanced stability protocols. CDMOs that excel here win repeat projects and elevate wallet share, reinforcing the upward trajectory of margins within the Vitamins, Minerals, and Supplements CDMO market.

By End-User: Nutraceutical Companies Dominate But Pharma Gains Traction

Nutraceutical companies generated 45.34% of revenue in 2025 and are expected to grow at a 10.65% CAGR. Their asset-light stance frees cash for influencer marketing and subscription platforms. Pharmaceutical firms, motivated by margin diversification, are scaling OTC wellness lines and leveraging pharmacy relationships. 

Consumer-health startups favor CDMOs that can manage thousands of tiny SKUs for personalized packs. Veterinary and medical-food producers round out demand. Packaging innovations, such as single-dose blister strips and child-resistant closures, require additional capital spending at CDMO sites but also create differentiation that locks in brand loyalty, expanding the addressable slice of the Vitamins, Minerals, and Supplements CDMO market.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America had the most significant regional footprint in 2025, anchored by the United States, where structure/function claims can appear on labels without pre-market approval. Certified facilities enjoy pricing power because retailers increasingly mandate third-party verification. Canada mirrors this dynamic, albeit at a smaller scale, and Mexican maquiladora hubs add flexible capacity for rapid replenishment. Between stringent oversight and mature retail channels, the region supplies a stable cash flow base for the wider Vitamins, Minerals, and Supplements CDMO market. 

Asia-Pacific delivers the fastest incremental revenue growth, benefiting from policy incentives such as India’s Production Linked Incentive scheme and China’s upgraded GB standards. Regional heavyweights, including Sirio Pharma, continue to add vegetarian capsule lines for export customers. Rapid urbanization fuels e-commerce penetration, making standardized supplements more accessible to first-time buyers. The blend of volume growth and rising regulatory expectations positions the area as the chief growth engine for the Vitamins, Minerals, and Supplements CDMO market. 

Europe remains fragmented. Germany exemplifies a pharmacy-centric sales model, France leans toward organic plant-based products, and the United Kingdom’s post-Brexit divergence adds compliance complexity. Southern nations such as Italy and Spain focus on Mediterranean-aligned nutrients, such as omega-3s and polyphenols. Outside the tri-continental core, Brazil’s e-commerce boom and GCC nations’ free-zone incentives create smaller but notable pockets of demand, each carving a place in the global Vitamins, Minerals, and Supplements CDMO market landscape.